Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, Alfonsi M, Janoray G, Chatellier T, Garcia-Ramirez M, Gherga E, Hammoud Y, Burgy M, Etienne-Selloum N, Pechery A, Girard-Calais MH, Velten M, Pignon JP, Wanneveich M, Bourhis J.
Borel C, et al. Among authors: sun xs.
Radiother Oncol. 2024 May 18:110329. doi: 10.1016/j.radonc.2024.110329. Online ahead of print.
Radiother Oncol. 2024.
PMID: 38768714